Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Microbiol.

Sec. Antimicrobials, Resistance and Chemotherapy

Volume 16 - 2025 | doi: 10.3389/fmicb.2025.1613987

This article is part of the Research TopicEmerging Antimicrobials: Sources, Mechanisms of Action, Spectrum of Activity, Combination Antimicrobial Therapy, and Resistance MechanismsView all 40 articles

Antifungal activity of cinnamaldehyde against Aspergillus fumigatus involves disruption of the TCA cycle and protein metabolism

Provisionally accepted
Fang  LiFang LiXi  ChengXi ChengLing  LiLing LiJinglu  JiangJinglu JiangYan  LiuYan LiuSiyu  MoSiyu MoWenxia  JiangWenxia JiangLi  LiuLi LiuSalem  BaldiSalem BaldiNanbiao  LongNanbiao Long*
  • Department of Medical Laboratory Diagnostics, School of Medical Technology, Shaoyang University, Shaoyang, China

The final, formatted version of the article will be published soon.

Aspergillus fumigatus is an environmental opportunistic fungal pathogen, which can lead to invasive aspergillosis in immunocompromised individuals, and resistant to conventional antifungual agents has become a growing concern. This study investigated the antifungal activity and the molecular antifungal mechanisms of Cinnamaldehyde (CA) against A. fumigatus, specifically its impact on metabolic pathways and protein metabolism. In susceptibility tests, CA was found to exhibit promising antifungal activity against A. fumigatus in both solid and liquid culture (biomass) systems, with the minimum inhibitory concentration (MIC) determined as 40–80 μg/mL. Quantitative spore viability assays under elevated CA concentrations demonstrated that the antifungal efficacy of CA against A. fumigatus is primarily attributable to its direct fungicidal mechanism. Interestingly, CA also showed equivalent antifungal activity against itraconazole- resistant strains R1(ITZ, MIC 8 μg/mL) and R2 (ITZ, MIC 8 μg/mL), as it did against its parental strain Af293(ITZ, MIC 1.5 μg/mL), suggesting its potential value to overcome resistance mechanisms associated with conventional antifungal therapies. Further proteomics and metabolomics analyses revealed that CA significantly affected the tricarboxylic acid (TCA) cycle and protein metabolism, with 167 differentially expressed proteins and 350 altered metabolites identified after 180 minutes of treatment (FC>2 or <0.5, p<0.05, VIP>1). Following treatment with CA, the protein expression of the putative translation initiation factor eIF4E3 (AFUB_051690), the putative leucyl-tRNA synthetase LeuRS (AFUB_093380), prolyl-tRNA synthetase ProRS (AFUB_010170) and the putative peptidyl-tRNA hydrolase Pth1 (AFUB_053480) exhibited a significant decrease. Moreover, deletion of pth1 resulted in a severe growth defect and hypersensitivity to CA, as evidenced by complete growth arrest at 30 and 45 μg/ml CA. Altogether, the results uncovered a novel antifungal mechanism of CA against A. fumigatus and suggest that CA or its derivatives could be developed as effective antifungal drugs.

Keywords: Aspergillus fumigatus, Cinnamaldehyde, Tricarboxylic acid (TCA) cycle, protein metabolism, itraconazole-resistant strains

Received: 18 Apr 2025; Accepted: 05 Aug 2025.

Copyright: © 2025 Li, Cheng, Li, Jiang, Liu, Mo, Jiang, Liu, Baldi and Long. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Nanbiao Long, Department of Medical Laboratory Diagnostics, School of Medical Technology, Shaoyang University, Shaoyang, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.